D-631-2013 Class III Terminated
FDA drug recall D-631-2013 was initiated by Pfizer Inc. on May 31, 2013 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the… The recall status is terminated (terminated Apr 6, 2017). Affected quantity: 135,520 blister cards.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 10, 2013
- Initiation Date
- May 31, 2013
- Termination Date
- Apr 6, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 135,520 blister cards
Product description
Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/5.0 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA 1910, NDC 0046-0975-11
Reason for recall
Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the specification for conjugated estrogens dissolution.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lots: E77055, E96153, & F11111 Exp: 06/13
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-631-2013
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026